-
Je něco špatně v tomto záznamu ?
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
A. Blauvelt, M. de Bruin-Weller, M. Gooderham, JC. Cather, J. Weisman, D. Pariser, EL. Simpson, KA. Papp, HC. Hong, D. Rubel, P. Foley, E. Prens, CEM. Griffiths, T. Etoh, PH. Pinto, RM. Pujol, JC. Szepietowski, K. Ettler, L. Kemény, X. Zhu, B....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest)
od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest)
od 1992-01-04 do Před 3 měsíci
- MeSH
- antiastmatika terapeutické užití MeSH
- atopická dermatitida farmakoterapie MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- hormony kůry nadledvin terapeutické užití MeSH
- injekce subkutánní MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- monoklonální protilátky terapeutické užití MeSH
- stupeň závažnosti nemoci MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Spojené státy americké MeSH
BACKGROUND: Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis. We aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-severe atopic dermatitis. METHODS: In this 1-year, randomised, double-blinded, placebo-controlled, phase 3 study (LIBERTY AD CHRONOS), adults with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids were enrolled at 161 hospitals, clinics, and academic institutions in 14 countries in Europe, Asia-Pacific, and North America. Patients were randomly assigned (3:1:3) to subcutaneous dupilumab 300 mg once weekly (qw), dupilumab 300 mg every 2 weeks (q2w), or placebo via a central interactive voice/web response system, stratified by severity and global region. All three groups were given concomitant topical corticosteroids with or without topical calcineurin inhibitors where inadvisable for topical corticosteroids. Topical corticosteroids could be tapered, stopped, or restarted on the basis of disease activity. Coprimary endpoints were patients (%) achieving Investigator's Global Assessment (IGA) 0/1 and 2-point or higher improvement from baseline, and Eczema Area and Severity Index 75% improvement from baseline (EASI-75) at week 16. Week 16 efficacy and week 52 safety analyses included all randomised patients; week 52 efficacy included patients who completed treatment by US regulatory submission cutoff. This study is registered with ClinicalTrials.gov, NCT02260986. FINDINGS: Between Oct 3, 2014, and July 31, 2015, 740 patients were enrolled: 319 were randomly assigned to dupilumab qw plus topical corticosteroids, 106 to dupilumab q2w plus topical corticosteroids, and 315 to placebo plus topical corticosteroids. 623 (270, 89, and 264, respectively) were evaluable for week 52 efficacy. At week 16, more patients who received dupilumab plus topical corticosteroids achieved the coprimary endpoints of IGA 0/1 (39% [125 patients] who received dupilumab plus topical corticosteroids qw and 39% [41 patients] who received dupilumab q2w plus topical corticosteroids vs 12% [39 patients] who received placebo plus topical corticosteroids; p<0·0001) and EASI-75 (64% [204] and 69% [73] vs 23% [73]; p<0·0001). Week 52 results were similar. Adverse events were reported in 261 (83%) patients who received dupilumab qw plus topical corticosteroids, 97 (88%) patients who received dupilumab q2w, and 266 (84%) patients who received placebo, and serious adverse events in nine (3%), four (4%), and 16 (5%) patients, respectively. No significant dupilumab-induced laboratory abnormalities were noted. Injection-site reactions and conjunctivitis were more common in patients treated with dupilumab plus topical corticosteroids-treated patients than in patients treated with placebo plus topical corticosteroids. INTERPRETATION: Dupilumab added to standard topical corticosteroid treatment for 1 year improved atopic dermatitis signs and symptoms, with acceptable safety. FUNDING: Sanofi and Regeneron Pharmaceuticals Inc.
Advanced Medical Research PC Atlanta GA USA
Australian National University Canberra and Probity Medical Research Phillip ACT Australia
Department of Dermatology and Allergology University of Szeged Szeged Hungary
Department of Dermatology Hospital del Mar Barcelona Spain
Department of Dermatology La Paz University Hospital Madrid Spain
Department of Dermatology Venereology and Allergology Wroclaw Poland
Dermatology and Venereology Hradec Kralove Czech Republic
Eastern Virginia Medical School and Virginia Clinical Research Inc Norfolk VA USA
Erasmus University Medical Center Rotterdam Rotterdam Netherlands
K Papp Clinical Research and Probity Medical Research Waterloo ON Canada
Modern Dermatology and Modern Research Associates and Probity Medical Research Dallas TX USA
Oregon Health and Science University Portland OR USA
Oregon Medical Research Center Portland OR USA
Regeneron Pharmaceuticals Inc Basking Ridge NJ USA
Regeneron Pharmaceuticals Inc Tarrytown NY USA
SKiN Centre for Dermatology Queen's University and Probity Medical Research Peterborough ON Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17030825
- 003
- CZ-PrNML
- 005
- 20171103101112.0
- 007
- ta
- 008
- 171025s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S0140-6736(17)31191-1 $2 doi
- 035 __
- $a (PubMed)28478972
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Blauvelt, Andrew $u Oregon Medical Research Center, Portland, OR, USA. Electronic address: ablauvelt@oregonmedicalresearch.com.
- 245 10
- $a Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial / $c A. Blauvelt, M. de Bruin-Weller, M. Gooderham, JC. Cather, J. Weisman, D. Pariser, EL. Simpson, KA. Papp, HC. Hong, D. Rubel, P. Foley, E. Prens, CEM. Griffiths, T. Etoh, PH. Pinto, RM. Pujol, JC. Szepietowski, K. Ettler, L. Kemény, X. Zhu, B. Akinlade, T. Hultsch, V. Mastey, A. Gadkari, L. Eckert, N. Amin, NMH. Graham, G. Pirozzi, N. Stahl, GD. Yancopoulos, B. Shumel,
- 520 9_
- $a BACKGROUND: Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Previous 16-week monotherapy studies showed that dupilumab substantially improved signs and symptoms of moderate-to-severe atopic dermatitis with acceptable safety, validating the crucial role of interleukin 4 and interleukin 13 in atopic dermatitis pathogenesis. We aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical corticosteroids in adults with moderate-to-severe atopic dermatitis. METHODS: In this 1-year, randomised, double-blinded, placebo-controlled, phase 3 study (LIBERTY AD CHRONOS), adults with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids were enrolled at 161 hospitals, clinics, and academic institutions in 14 countries in Europe, Asia-Pacific, and North America. Patients were randomly assigned (3:1:3) to subcutaneous dupilumab 300 mg once weekly (qw), dupilumab 300 mg every 2 weeks (q2w), or placebo via a central interactive voice/web response system, stratified by severity and global region. All three groups were given concomitant topical corticosteroids with or without topical calcineurin inhibitors where inadvisable for topical corticosteroids. Topical corticosteroids could be tapered, stopped, or restarted on the basis of disease activity. Coprimary endpoints were patients (%) achieving Investigator's Global Assessment (IGA) 0/1 and 2-point or higher improvement from baseline, and Eczema Area and Severity Index 75% improvement from baseline (EASI-75) at week 16. Week 16 efficacy and week 52 safety analyses included all randomised patients; week 52 efficacy included patients who completed treatment by US regulatory submission cutoff. This study is registered with ClinicalTrials.gov, NCT02260986. FINDINGS: Between Oct 3, 2014, and July 31, 2015, 740 patients were enrolled: 319 were randomly assigned to dupilumab qw plus topical corticosteroids, 106 to dupilumab q2w plus topical corticosteroids, and 315 to placebo plus topical corticosteroids. 623 (270, 89, and 264, respectively) were evaluable for week 52 efficacy. At week 16, more patients who received dupilumab plus topical corticosteroids achieved the coprimary endpoints of IGA 0/1 (39% [125 patients] who received dupilumab plus topical corticosteroids qw and 39% [41 patients] who received dupilumab q2w plus topical corticosteroids vs 12% [39 patients] who received placebo plus topical corticosteroids; p<0·0001) and EASI-75 (64% [204] and 69% [73] vs 23% [73]; p<0·0001). Week 52 results were similar. Adverse events were reported in 261 (83%) patients who received dupilumab qw plus topical corticosteroids, 97 (88%) patients who received dupilumab q2w, and 266 (84%) patients who received placebo, and serious adverse events in nine (3%), four (4%), and 16 (5%) patients, respectively. No significant dupilumab-induced laboratory abnormalities were noted. Injection-site reactions and conjunctivitis were more common in patients treated with dupilumab plus topical corticosteroids-treated patients than in patients treated with placebo plus topical corticosteroids. INTERPRETATION: Dupilumab added to standard topical corticosteroid treatment for 1 year improved atopic dermatitis signs and symptoms, with acceptable safety. FUNDING: Sanofi and Regeneron Pharmaceuticals Inc.
- 650 _2
- $a hormony kůry nadledvin $x terapeutické užití $7 D000305
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antiastmatika $x terapeutické užití $7 D018927
- 650 _2
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 _2
- $a atopická dermatitida $x farmakoterapie $7 D003876
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a injekce subkutánní $7 D007279
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a Spojené státy americké $7 D014481
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a de Bruin-Weller, Marjolein $u University Medical Center Utrecht, Utrecht, Netherlands.
- 700 1_
- $a Gooderham, Melinda $u SKiN Centre for Dermatology, Queen's University, and Probity Medical Research, Peterborough, ON, Canada.
- 700 1_
- $a Cather, Jennifer C $u Modern Dermatology and Modern Research Associates, and Probity Medical Research, Dallas, TX, USA.
- 700 1_
- $a Weisman, Jamie $u Advanced Medical Research, PC, Atlanta, GA, USA.
- 700 1_
- $a Pariser, David $u Eastern Virginia Medical School and Virginia Clinical Research Inc, Norfolk, VA, USA.
- 700 1_
- $a Simpson, Eric L $u Oregon Health and Science University, Portland, OR, USA.
- 700 1_
- $a Papp, Kim A $u K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada.
- 700 1_
- $a Hong, H Chih-Ho $u Department of Dermatology and Skin Science, University of British Columbia, and Probity Medical Research, Surrey, BC, Canada.
- 700 1_
- $a Rubel, Diana $u Australian National University, Canberra, and Probity Medical Research, Phillip, ACT, Australia.
- 700 1_
- $a Foley, Peter $u The University of Melbourne, Parkville, Skin & Cancer Foundation Inc, Carlton, and Probity Medical Research, Carlton, VIC, Australia.
- 700 1_
- $a Prens, Errol $u Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.
- 700 1_
- $a Griffiths, Christopher E M $u The Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
- 700 1_
- $a Etoh, Takafumi $u Tokyo Teishin Postal Services Agency Hospital, Tokyo, Japan.
- 700 1_
- $a Pinto, Pedro Herranz $u Department of Dermatology, La Paz University Hospital, Madrid, Spain.
- 700 1_
- $a Pujol, Ramon M $u Department of Dermatology, Hospital del Mar, Barcelona, Spain.
- 700 1_
- $a Szepietowski, Jacek C $u Department of Dermatology, Venereology and Allergology, Wroclaw, Poland.
- 700 1_
- $a Ettler, Karel $u Dermatology and Venereology, Hradec Kralove, Czech Republic.
- 700 1_
- $a Kemény, Lajos $u Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
- 700 1_
- $a Zhu, Xiaoping $u Regeneron Pharmaceuticals Inc, Basking Ridge, NJ, USA.
- 700 1_
- $a Akinlade, Bolanle $u Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA. $7 gn_A_00002955
- 700 1_
- $a Hultsch, Thomas $u Sanofi, Cambridge, MA, USA.
- 700 1_
- $a Mastey, Vera $u Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
- 700 1_
- $a Gadkari, Abhijit $u Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
- 700 1_
- $a Eckert, Laurent $u Sanofi, Chilly-Mazarin, France.
- 700 1_
- $a Amin, Nikhil $u Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA. $7 gn_A_00005589
- 700 1_
- $a Graham, Neil M H $u Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
- 700 1_
- $a Pirozzi, Gianluca $u Sanofi, Bridgewater, NJ, USA.
- 700 1_
- $a Stahl, Neil $u Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
- 700 1_
- $a Yancopoulos, George D $u Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
- 700 1_
- $a Shumel, Brad $u Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.
- 773 0_
- $w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 389, č. 10086 (2017), s. 2287-2303
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28478972 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171103101206 $b ABA008
- 999 __
- $a ok $b bmc $g 1254418 $s 991852
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 389 $c 10086 $d 2287-2303 $e 20170504 $i 1474-547X $m Lancet $n Lancet $x MED00010161
- LZP __
- $a Pubmed-20171025
